Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dutch Researcher Focuses on Fc Signaling in Targeting CD20

April 25th 2013

Jeanette H.W. Leusen, PhD, focuses on studying the working mechanisms of therapeutic antibodies and the biology of fragment crystallizable receptors, including the anti-CD20 monoclonal antibody rituximab in patients with non-Hodgkin lymphoma.

Dr. Richard Silver Discusses the High Cost of Drugs in CML

April 24th 2013

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Dr. Pinter-Brown on Treating CTCL With Chemotherapy

April 22nd 2013

Lauren Pinter-Brown, MD, from the University of California, Los Angeles, gives an overview of treatment with chemotherapy for patients with cutaneous T-cell lymphoma.

Dr. Advani Discusses CD30 as a Target in ALCL

April 18th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

April 17th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.

Dr. Ruben Mesa on Late-Stage Trials in Myelofibrosis

April 15th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

Dr. Ari M. Melnick on Biomarkers in Lymphoma

April 11th 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Dr. Landgren on Carfilzomib and Pomalidomide

April 10th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Dr. Erba on the Diagnosis and Testing of Patients with CML

April 9th 2013

Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, comments on the diagnosis and testing of a patient with chronic myeloid leukemia (CML).

Numerous Drug Classes Studied for Use in Follicular Lymphoma

April 9th 2013

Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.

Ibrutinib Receives Additional Breakthrough Designation for CLL

April 8th 2013

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Dr. Cheson on the Diagnosis of Follicular Lymphoma

April 8th 2013

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, discusses the diagnosis of patients with follicular lymphoma.

Dr. Berenson Discusses New Potential Targets in Myeloma

April 4th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Dr. Silver on Hydroxyurea and Interferon in MPNs

April 3rd 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use hydroxyurea and interferons in myeloproliferative neoplasms.

Dr. Pinter-Brown on Treatment Expectations in CTCL

April 2nd 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma.

Dr. Jennifer Brown on Mutations and Targets in CLL

April 1st 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.

Interferon Therapy: A Growing Family Feeds New Interest in an Older Treatment

April 1st 2013

Interferons have evolved from a "cure-all" for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of different disease states, including many different types of cancer.

Dr. Landgren Discusses Risk and Treatment in Myeloma

March 28th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Seeking a Standard in the Treatment of Elderly Patients With CLL

March 28th 2013

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

March 28th 2013

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.